Abstract:
This commentary proposes that Rasch Measurement Theory (RMT) is an innovative method for assessments of patient-centric therapy response in hemophilia A and B, as they are in other disease states or target patient populations. RMT is a necessary and sufficient approach to moving from ordinal observations to interval measurement, which has arithmetic properties. This applies across the board in hemophilia and other disease states for clinical value claims, patient centric or subjective value claims as well as those for anticipated drug utilization and other medical care resources. The purpose of this commentary is to point out limitations regarding current methods for making claims regarding hemophilia response and to propose a new start in hemophilia studies to identify core claims that meet required measurement standards. This applies to both the development of new patient reported outcome instruments as well as the evaluation of existing instruments, with a focus on polytomous instruments and their sub-domains, to evaluate their possible application as measures that approximate RMT requirements.
摘要:
这篇评论提出,Rasch测量理论(RMT)是一种创新的方法,用于评估A和B血友病的以患者为中心的治疗反应。与其他疾病状态或目标患者人群一样。RMT是从顺序观察到间隔测量的必要和充分的方法,它具有算术属性。这适用于血友病和其他疾病状态的临床价值声明,以患者为中心或主观价值主张,以及预期的药物利用和其他医疗资源。本评论的目的是指出当前对血友病反应提出索赔的方法的局限性,并提出血友病研究的新起点,以确定符合所需测量标准的核心索赔。这既适用于新的患者报告结果工具的开发,也适用于现有工具的评估。专注于多体乐器及其子领域,评估其可能的应用,作为接近RMT要求的措施。